NCT01938846View on ClinicalTrials.gov

BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 5, 2013

Primary Completion Date

July 30, 2016

Study Completion Date

June 22, 2017

Conditions
Neoplasms
Interventions
DRUG

BI 860585

BI 860585 multiple dose escalation, once daily

DRUG

exemestane

exemestane once daily

DRUG

BI 860585

BI 860585 multiple dose escalation, once daily

DRUG

BI 860585

BI 860585 multiple dose escalation, once daily

DRUG

paclitaxel

paclitaxel once weekly

Trial Locations (4)

1200

Brussels - UNIV Saint-Luc, Brussels

9000

UNIV UZ Gent, Ghent

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

43126

Azienda Ospedaliera di Parma, Parma

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter